LIVE MARKET TRACKER :   BSE SENSEX   31922.44      |    NSE NIFTY 9964.40    
GLOBAL MARKETS :  NASDAQ 6426.922   +0.066%    |    FSI London 7310.64   +0.64%    |    NIKKEI Japan 20296.45   -0.25%
  USD GBP EUR CAD AUD INR
USD - 0.7410 0.8370 1.2338 1.2553 64.8390
GBP 1.3498 - 1.1298 1.6647 1.6950 87.4238
EUR 1.1951 0.8856 - 1.4714 1.4981 77.4119
CAD 0.8120 0.6018 0.6793 - 1.0185 52.6090
AUD 0.7968 0.5911 0.6671 0.9833 - 51.6360
INR 0.0154 0.0115 0.0129 0.0191 0.0194 -
Indian-Commodity  :  Top News  :  Lupin, Coromandel International and AstraZeneca to see some action today

Lupin, Coromandel International and AstraZeneca to see some action today (24-Jul-2017)

US Food and Drug Administration (USFDA) has successfully completed Prior Approval Inspection (PAI) at Lupin's Goa manufacturing facility without any observations. The inspection which started on July 17 concluded on July 21, 2017. Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Coromandel International has received environmental clearance for raising production capacity of its facility at Vishakhapatnam in Andhra Pradesh. The environment clearance to Rs 225-crore expansion project is subject to the compliance of specific and general conditions. The company's proposal is to raise phosphoric acid production capacity from 700 tonnes per day to 1,000 tonnes per day and other auxiliary facilities at Sriharipuram to achieve daily complex fertiliser production of 3,900 tonnes.

AstraZeneca Pharma India will be launching Osimertinib 40 mg and 80 mg (Tagrisso) in India on July 27, 2017. Osimertinib 40 mg and 80 mg (Tagrisso) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy. Osimertinib (Tagrisso) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

Persistent Systems' wholly owned subsidiary in Germany namely, Persistent Systems Germany GmbH has entered into an agreement with PARX Werk AG, Switzerland (PARX) on July 21, 2017 to acquire PARX, a Salesforce Certified Platinum Partner in DACH region. The acquisition is subject to customary closing conditions which are expected to get completed within 3-4 weeks. The consideration would be in cash. The proposed acquisition strengthens Persistent's Salesforce practice through entry into new markets as well as provides new capabilities to support customers on their digital transformation initiatives.  

Vikas WSP has received export orders for an aggregate amount of Rs 119 crore for shipment of its newly developed guar gum product 'Thermo Guar-30' in the next two quarters. The company has already filed patent for the said product. Vikas WSP is one of India's foremost guar gum powder (GGP) manufacturer, supplying to all sectors of the food industry with an extensive range of quality products.

Speciality Restaurants has opened a new POH (Progressive Oriental House) restaurant at Mumbai. As continuation of the company's determination to dominate in Chinese and Pan Asian Market in India, the company has given birth to a new boutique oriental restaurant called Progressive Oriental House. This restaurant at Kamala Mills, Mumbai is targeted towards creme de la creme and HNI's, who are looking for newer flavours and experience.



Top News Today
REC gets nod to raise Rs 65,000 crore via bonds
(23-Sep-2017)

REC gets nod to raise Rs 65,000 crore via bondsRural Electrification Corporation (REC) has received shareholders' approval to raise up to Rs 65,000 crore via bonds over the next one year. The special resolution was passed at the company's annual general......click on news to read complete article.

BNP Paribas Arbitrage sells 1.40 lakh shares of Matrimony.com
(23-Sep-2017)

BNP Paribas Arbitrage sells 1.40 lakh shares of Matrimony.comBNP Paribas Arbitrage has sold 1.40 lakh shares of Matrimony.com. The fund house has offloaded the same at Rs 817.73 on the NSE on September 22, 2017.Recently, BNP Paribas Arbitrage has offloaded 1,34,102......click on news to read complete article.

Corporation San Finance buys 8.77 lakh shares of Bharat Road Network
(23-Sep-2017)

Corporation San Finance buys 8.77 lakh shares of Bharat Road NetworkCorporation San Finance has bought 8.77 lakh shares of Bharat Road Network. The company has bought these shares at Rs 189.81 on the NSE on September 22, 2017.Recently, Bharat Road raised Rs 600 crore through......click on news to read complete article.

International Stock News
US markets end flat on geopolitical concerns
(23-Sep-2017)

US markets end flat on geopolitical concernsThe US markets ended the lackluster session near their neutral lines on Friday on geopolitical concerns amid an escalating war of words between North Korean leader Kim Jong Un and President Donald Trump.......click on news to read complete article.

Asian markets trade lower on heightened geopolitical tensions
(22-Sep-2017)

Asian markets trade lower on heightened geopolitical tensionsThe Asian markets are showing a weak trend on Friday, on renewed geopolitical worries after a report that North Korea could respond to fresh sanctions with a hydrogen bomb in the Pacific. A news report......click on news to read complete article.

US markets closed lower; Dow snaps nine-day winning streak
(22-Sep-2017)

US markets closed lower; Dow snaps nine-day winning streakThe US markets closed lower on Thursday, with the Dow snapping a nine-day winning streak as investors found few reasons to chase equities a day after the Federal Reserve indicated it still intends to deliver......click on news to read complete article.

 

     
  
Recent Top News News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.